177Lu-RM2 (177Lu-BAY-1017858) is a molecule corresponding to a different than PSMA biological approach for treating prostate cancer developed originally at Bayer. Unfortunately, it does not seem this molecule is presently supported by a private group, but some research was reactivated in 2020.
177Lu-RM2 efficiently targets the BB2r (Bombesin receptor 2) expressed on CRPC cells in vivo. This molecule is associated to the diagnostic agent 68Ga-Bombesin (68Ga-RM2).
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.